Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.3, and our video podcast, CANCER BUZZ TV.

Industry News Archives

FDA Approves Isatuximab in Combination for R/R Multiple Myeloma

On March 31, 2021, the U.S. Food and Drug Administration (FDA) approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma who have received one to three prior lines of therapy.

Read the FDA announcement.

Read the Sanofi announcement.

Posted 4/1/2021


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
rmos-colorado.com
Email Us